Mobidiag Ltd have received CE-IVD marking for the Amplidiag® CarbaR+MCR, a molecular test allowing detection of the main carbapenemase-producing organisms and colistin resistance markers in one single test.

Antimicrobial resistance is currently one of the biggest threats to global health. Mobidiag has been developing innovative diagnostic tools based on its proprietary technologies and patents covering screening method and related kits for carbapenemase genes responsible for carbapenem resistance in bacteria. The new Amplidiag® CarbaR+MCR test, along with existing Amplidiag® CarbaR+VRE, allow patient screening for multidrug resistant organisms to prevent their spreading in hospital environment.

“By obtaining the CE-IVD marking, the Amplidiag CarbaR+MCR test complement the currently available carbapenemases and resistances panel strengthening our commitment towards the fight against antibiotic resistance. Indeed Mobidiag has been using its expertise in the detection of gastrointestinal infections to combat multi-drug resistant organisms, a key application in our global strategy” said Tuomas Tenkanen, CEO at Mobidiag.

Amplidiag® CarbaR+MCR test is now available directly through Mobidiag and local distributors. For more information, visit mobidiag.com.